Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
that is becouse this is not run like a otc company. this is a investment not a flip and make money quick. some are but find out they got out to early and want back in at a lower pps. they are chasing stares and cant catch it as they are not going to make what they would have if they held on . weak hands lose strong hands win. you dont loss or gain until you sell. we know the company will prevail in the long run.
this is good news i love it
your welcome
here put up the whole truth not just part of it the company will be ok. they have keep working and things are moving forward here with sohm increased revs a product a market for the product etc.
now for the facts you bring here . everyone can gather there own inference from the info i provide here as we all know what mine is i am here for the long hall.
Fleetsafer in the uk
if cogosense had nothing to do with us the company would not have invested 1,875,000 into cogosense to purchase it as of date
FleetSafer
CFS is a nationwide buying services program that meets the needs of light, medium, and heavy-duty fleets.
All Rights Reserved ©2021
http://www.consolidatedfleetsolutions.com/default.aspx
Lower operating expenses
As a member, you’ll enjoy lower operating expenses as Consolidated Fleet Solutions streamlines vendor coordination and provides you with rebates, discounts, purchase incentives, and exclusive access to greater purchasing power.
Benefits for all your departments
CFS offers you a comprehensive portfolio of top suppliers and services touching multiple categories, including:
Trucks
Vehicle Parts and Supplies
DEF Equipment
DEF Fuel
DOT Background Checks
Facility Maintenance
Office Supplies
Financial Services
Alliances with leading companies
Save money without taking shortcuts on quality. CFS connects you to the top names in the business.
No hassles
How do you take advantage of all your CFS benefits? Keep buying directly from your suppliers, just as you have been. CFS benefits are above and beyond what you’re receiving from your suppliers.
http://www.consolidatedfleetsolutions.com/contact.html
An estimated 26% of vehicle accidents are due to distracted driving. Which can be preventable with FleetSafer®!
read more
http://www.consolidatedfleetsolutions.com/FleetSafer.html
Cogosense
https://pitchbook.com/profiles/company/180145-36#overview
Exit Report Under Regulation a (1-z)
March 09 2021 - 03:33PM
Edgar (US Regulatory)
Form 1-Z Issuer Information
Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination? x Yes o No
https://ih.advfn.com/stock-market/USOTC/on4-communications-pk-ONCI/stock-news/84535573/exit-report-under-regulation-a-1-z
On4 Communications, Inc.
ONCI
https://sec.report/otc/company/ONCI#documents
we need to remember that sohm is also in india as sohm pvt witch would be getting paid in rupee. now with that said one rupee equals 0.014 in U.S. money https://www.bing.com/search?FORM=SLBRDF&PC=SL13&q=what+is+the+convertion+of+one+rs+to+the+us+dollar
as sohm dose private label here is something else to look at
7 K-Gesic Tablet Ibuprofen 400 Mg. Paracetamol – 500 Mg. 10 X 10 Blister https://www.sohm.com/product/analgesic/
Anti Inflammatory and Analgesic Tablets
Get Latest Price
Supply TypeExporters, Suppliers
The company is proficient is manufacturing, exporting and supplying highly acclaimed Anti Inflammatory and Analgesic Tablets. Customers can avail Anti Inflammatory and Analgesic Tablets like K-gesic tablets from us as per the requirement. We recommend the prescribed dosage of our Anti Inflammatory and Analgesic Tablets for effective pain treatment.
Composition : Ibuprofen IP 400 MG + Paracetamol IP 500 MG
Caution : Bronchospam may be precipitated in patient suffering from or with a previous history of bronchial asthma. Ibuprofen should not to be given to patients in whom aspirin and other non-steroidal anti inflammatory drugs induce the symptoms of asthma, rhinitis or urticaria.
Company Detail
Business TypeExporters / Suppliers
Member Since2014
https://www.exportersindia.com/product-detail/anti-inflammatory-and-analgesic-tablets-paonta-sahib-india-827272.htm
Upkar Pharmaceuticals
Anti Inflammatory and Analgesic Tablets
The company is proficient is manufacturing, exporting and supplying highly acclaimed Anti Inflammatory and Analgesic Tablets . Customers can avail Anti Inflammatory and Analgesic Tablets like K-gesic tablets from us as per the requirement. We recommend the prescribed dosage of our Anti Inflammatory and Analgesic Tablets for effective pain treatment. Composition : Ibuprofen IP 400 MG + Paracetamol IP 500 MG Caution : Bronchospam may be precipitated in patient suffering from or with a previous history of bronchial asthma. Ibuprofen should not to be given to patients in whom aspirin and other non-steroidal anti inflammatory drugs induce the symptoms of asthma, rhinitis or urticaria.
https://www.exportersindia.com/upkar-pharmaceuticals/anti-inflammatory-drugs.htm#827272
this is from the wholesale supplier
https://www.indiamart.com/proddetail/chloroquine-phosphate-injection-21673859973.html
Ivermectin brand name Stromectol is not in the list of drugs from sohm any were you can look here https://www.sohm.com/products/ . we do have chloroquin though it is called jetquin .
8 Inj. Jetquin Chloroquin 40mg/ ml 5ML AMP 25
9 Inj. Jetquin Chloroquin 40mg / ml 30ML VIAL 25
you can find that here https://www.sohm.com/product/injections/
but anyway here is the info on ivermectin
Ivermectin
Generic Name: ivermectin (oral) (EYE ver MEK tin)
Brand Name: Stromectol
What is ivermectin?
Ivermectin is an anti-parasite medication.
Ivermectin is used to treat infections in the body that are caused by certain parasites.
Ivermectin is currently being investigated as a treatment for coronavirus SARS-CoV-2, which is the virus that causes COVID-19. The trials so far have shown ivermectin reduces the number of cell-associated viral DNA by 99.8 % in 24 hours. Further studies are needed to determine the effectiveness of this medicine in humans with COVID-19.
Click for further information on using ivermectin to treat COVID-19 and other prevention and investigational treatments.
read in full here
https://www.drugs.com/ivermectin.html
here is info on Chloroquine or Hydroxychloroquine
Chloroquine or Hydroxychloroquine With or Without Azithromycin
Last Updated: October 9, 2020
Chloroquine is an antimalarial drug that was developed in 1934. Hydroxychloroquine, an analogue of chloroquine, was developed in 1946. Hydroxychloroquine is used to treat autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis, in addition to malaria. In general, hydroxychloroquine has fewer and less severe toxicities (including less propensity to prolong the QTc interval) and fewer drug-drug interactions than chloroquine.
Both chloroquine and hydroxychloroquine increase the endosomal pH, inhibiting fusion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the host cell membranes.1 Chloroquine inhibits glycosylation of the cellular angiotensin-converting enzyme 2 receptor, which may interfere with binding of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) to the cell receptor.2 In vitro studies have suggested that both chloroquine and hydroxychloroquine may block the transport of SARS-CoV-2 from early endosomes to endolysosomes, possibly preventing the release of the viral genome.3 Both chloroquine and hydroxychloroquine also have immunomodulatory effects. It has been hypothesized that these effects are other potential mechanisms of action for the treatment of COVID-19. However, despite demonstrating antiviral activity in some in vitro systems, hydroxychloroquine with or without azithromycin did not reduce upper or lower respiratory tract viral loads or demonstrate clinical efficacy in a rhesus macaque model.4
Chloroquine and hydroxychloroquine, with or without azithromycin, have been studied in multiple clinical trials for the treatment of COVID-19. The recommendations below are based on an assessment of the collective evidence from these studies.
Recommendations
The COVID-19 Treatment Guidelines Panel (the Panel) recommends against the use of chloroquine or hydroxychloroquine with or without azithromycin for the treatment of COVID-19 in hospitalized patients (AI).
In nonhospitalized patients, the Panel recommends against the use of chloroquine or hydroxychloroquine with or without azithromycin for the treatment of COVID-19, except in a clinical trial (AIIa).
The Panel recommends against the use of high-dose chloroquine (600 mg twice daily for 10 days) for the treatment of COVID-19 (AI).
Rationale
The safety and efficacy of chloroquine and hydroxychloroquine with or without azithromycin have been evaluated in randomized clinical trials, observational studies, and single-arm studies. Please see Table 2b for more information.
In a large randomized controlled trial of hospitalized patients in the United Kingdom, hydroxychloroquine did not decrease 28-day mortality when compared to the usual standard of care. Participants who were randomized to receive hydroxychloroquine had a longer median hospital stay than those who received the standard of care. In addition, among patients who were not on invasive mechanical ventilation at the time of randomization, those who received hydroxychloroquine were more likely to subsequently require intubation or die during hospitalization than those who received the standard of care.5
In another randomized controlled trial that was conducted in Brazil, neither hydroxychloroquine alone nor hydroxychloroquine plus azithromycin improved clinical outcomes among hospitalized patients with mild to moderate COVID-19. More adverse events occurred among patients who received hydroxychloroquine or hydroxychloroquine plus azithromycin than among those who received the standard of care.6 Data from another randomized study of hospitalized patients with severe COVID-19 do not support using hydroxychloroquine plus azithromycin over hydroxychloroquine alone.7
In addition to these randomized trials, data from large retrospective observational studies do not consistently show evidence of a benefit for hydroxychloroquine with or without azithromycin in hospitalized patients with COVID-19. For example, in a large retrospective observational study of patients who were hospitalized with COVID-19, hydroxychloroquine use was not associated with a reduced risk of death or mechanical ventilation.8 Another multicenter retrospective observational study evaluated the use of hydroxychloroquine with and without azithromycin in a random sample of a large cohort of hospitalized patients with COVID-19.9 Patients who received hydroxychloroquine with or without azithromycin did not have a decreased risk of in-hospital mortality when compared to those who received neither hydroxychloroquine nor azithromycin.
Conversely, a large retrospective cohort study reported a survival benefit among hospitalized patients who received either hydroxychloroquine alone or hydroxychloroquine plus azithromycin, compared to those who received neither drug.10 However, patients who did not receive hydroxychloroquine had a lower rate of admission to the intensive care unit, which suggests that patients in this group may have received less-aggressive care. Furthermore, a substantially higher percentage of patients in the hydroxychloroquine arms also received corticosteroids (77.1% of patients in the hydroxychloroquine arms vs. 36.5% of patients in the control arm). Given that the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial showed that corticosteroids improve the survival rate of patients with COVID-19 (see Corticosteroids), it is possible that the findings in this study were confounded by this imbalance in corticosteroid use.11 These and other observational and single-arm studies are summarized in Table 2b.
Many of the observational studies that have evaluated the use of chloroquine or hydroxychloroquine in patients with COVID-19 have attempted to control for confounding variables. However, study arms may be unbalanced in some of these studies, and some studies may not account for all potential confounding factors. These factors limit the ability to interpret and generalize the results from observational studies; therefore, results from these studies are not as definitive as those from large randomized trials. Given the lack of a benefit seen in the randomized clinical trials and the potential for toxicity, the Panel recommends against using hydroxychloroquine or chloroquine with or without azithromycin to treat COVID-19 in hospitalized patients (AI).
The Panel also recommends against using high-dose chloroquine to treat COVID-19 (AI). High-dose chloroquine (600 mg twice daily for 10 days) has been associated with more severe toxicities than lower-dose chloroquine (450 mg twice daily for 1 day, followed by 450 mg once daily for 4 days). A randomized clinical trial compared the use of high-dose chloroquine and low-dose chloroquine in hospitalized patients with severe COVID-19. In addition, all participants received azithromycin, and 89% of the participants received oseltamivir. The study was discontinued early when preliminary results showed higher rates of mortality and QTc prolongation in the high-dose chloroquine group.12
Several randomized trials have not shown a clinical benefit for hydroxychloroquine in nonhospitalized patients with COVID-19. However, other clinical trials are still ongoing.13,14 In nonhospitalized patients, the Panel recommends against the use of chloroquine or hydroxychloroquine with or without azithromycin for the treatment of COVID-19, except in a clinical trial (AIIa).
The combination of hydroxychloroquine and azithromycin is associated with QTc prolongation in patients with COVID-19. Given the long half-lives of both azithromycin (up to 72 hours) and hydroxychloroquine (up to 40 days), caution is warranted even when the two drugs are used sequentially instead of concomitantly.15
Please see Table 2b for additional details.
Adverse Effects
Chloroquine and hydroxychloroquine have a similar toxicity profile, although hydroxychloroquine is better tolerated and has a lower incidence of toxicity than chloroquine.
Cardiac Adverse Effects
QTc prolongation, Torsade de Pointes, ventricular arrythmia, and cardiac deaths.16 If chloroquine or hydroxychloroquine is used, clinicians should monitor the patient for adverse events, especially prolonged QTc interval (AIII).
The risk of QTc prolongation is greater for chloroquine than for hydroxychloroquine.
Concomitant medications that pose a moderate to high risk for QTc prolongation (e.g., antiarrhythmics, antipsychotics, antifungals, macrolides [including azithromycin],16 fluoroquinolone antibiotics)17 should be used only if necessary. Consider using doxycycline rather than azithromycin as empiric therapy for atypical pneumonia.
Multiple studies have demonstrated that concomitant use of hydroxychloroquine and azithromycin can prolong the QTc interval;18-20 in an observational study, the use of hydroxychloroquine plus azithromycin was associated with increased odds of cardiac arrest.9 The use of this combination warrants careful monitoring.
Baseline and follow-up electrocardiograms are recommended when there are potential drug interactions with concomitant medications (e.g., azithromycin) or underlying cardiac diseases.21
The risk-benefit ratio should be assessed for patients with cardiac disease, a history of ventricular arrhythmia, bradycardia (<50 bpm), or uncorrected hypokalemia and/or hypomagnesemia.
Other Adverse Effects
Hypoglycemia, rash, and nausea. Divided doses may reduce nausea.
Retinopathy. Bone marrow suppression may occur with long-term use, but this is not likely with short-term use.
Drug-Drug Interactions
Chloroquine and hydroxychloroquine are moderate inhibitors of cytochrome P450 (CYP) 2D6, and these drugs are also P-glycoprotein (P-gp) inhibitors. Use caution when administering these drugs with medications that are metabolized by CYP2D6 (e.g., certain antipsychotics, beta-blockers, selective serotonin reuptake inhibitors, methadone) or transported by P-gp (e.g., certain direct-acting oral anticoagulants, digoxin).22 Chloroquine and hydroxychloroquine may decrease the antiviral activity of remdesivir; coadministration of these drugs is not recommended.23
Considerations in Pregnancy
Antirheumatic doses of chloroquine and hydroxychloroquine have been used safely in pregnant women with SLE.
Hydroxychloroquine exposure has not been associated with adverse pregnancy outcomes in =300 human pregnancies.
A lower dose of chloroquine (500 mg once a week) is used for malaria prophylaxis during pregnancy.
No dose changes are necessary for chloroquine or hydroxychloroquine during pregnancy.
Considerations in Children
Chloroquine and hydroxychloroquine have been routinely used in pediatric populations for the treatment and prevention of malaria and for rheumatologic conditions.
Drug Availability
Hydroxychloroquine, chloroquine, and azithromycin are not approved by the Food and Drug Administration (FDA) for the treatment of COVID-19.
Hydroxychloroquine is approved by the FDA for the treatment of malaria, lupus erythematosus, and rheumatoid arthritis. Chloroquine is approved for the treatment of malaria and extraintestinal amebiasis. Azithromycin is commonly used for the treatment and/or prevention of nontuberculous mycobacterial infection, various sexually transmitted infections, and various bacterial infections.
source
https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/chloroquine-or-hydroxychloroquine-with-or-without-azithromycin/
here is a repost. its a post i put up last night
SOHM Inc (OTCMKTS:SHMN) Set To Acquire A New Pharmaceutical Company After Signing A Letter Of Intent
David Fisher | April 28, 2021
SOHM Inc (OTCMKTS:SHMN) is pleased to announce the purchase of a Pharmaceutical company located in Southern California. It confirms that it signed a Letter of Intent to win the new acquisition, terming it a great addition to its assets.
Mr. Baron speaks out on the latest move
The CEO of SOHM, Mr. Baron Night, seems pleased with the company’s latest move in his recent speech. The official spoke about how they continue channeling their resources and efforts in their products’ marketing and manufacturing activities. SOHM deals in Cosmeceuticals, Pharmaceutical, Nutraceutical, and Personal care products. The company undertakes most of its business operations within the United States.
Mr. Night applauds SOHM for its successful acquisition of the Southern California company, terming the move a logical expansion focused on building its brand name. He recognizes the fast growth within the OTC and the generic prescription pharmaceutical segment in the United States, outlining that such change inspires them to strive to remain at the top of their game. The new acquisition is one of several the company eyes in the future as part of its business growth and expansion goals.
Need for due diligence
Mr. Night regards this possible acquisition to be a tremendous step forward for the company but reminds the shareholders about due diligence as a responsibility. He says that the company is doing all within its means to speed up the process, outlining that success in this direction will enable them to set up an outstanding distribution network in the various states.
SOHM will utilize its Southern California manufacturing facility to develop its diverse products. The plan is to undertake all manufacturing activities in-house. Night believes that the company’s latest undertakings will guarantee it increased profits soon.
SOHM aspires to achieve massive business growth and stability and hopes that bringing together the two companies’ strengths will make things work out.
Mr. Night calls refers to the new deal as one of SOHM’s organic takeovers. According to the leader, they must observe due diligence, and everything must happen on a cash basis. SOHM focuses on its push for due diligence, after which it will make its definitive agreement pronouncement.
source
https://drpgazette.com/2021/04/28/sohm-inc-otcmktsshmn-set-to-acquire-a-new-pharmaceutical-company-after-signing-a-letter-of-intent/
it was just a thought
or they are buying shares back on the open market
i think we are going to see a huge squeeze here
that could be.
that would be it
it is also done in cash no notes or toxic debit
that makes two of us
sohm something i found of interest here
SOHM Inc (OTCMKTS:SHMN) Set To Acquire A New Pharmaceutical Company After Signing A Letter Of Intent
David Fisher | April 28, 2021
SOHM Inc (OTCMKTS:SHMN) is pleased to announce the purchase of a Pharmaceutical company located in Southern California. It confirms that it signed a Letter of Intent to win the new acquisition, terming it a great addition to its assets.
Mr. Baron speaks out on the latest move
The CEO of SOHM, Mr. Baron Night, seems pleased with the company’s latest move in his recent speech. The official spoke about how they continue channeling their resources and efforts in their products’ marketing and manufacturing activities. SOHM deals in Cosmeceuticals, Pharmaceutical, Nutraceutical, and Personal care products. The company undertakes most of its business operations within the United States.
Mr. Night applauds SOHM for its successful acquisition of the Southern California company, terming the move a logical expansion focused on building its brand name. He recognizes the fast growth within the OTC and the generic prescription pharmaceutical segment in the United States, outlining that such change inspires them to strive to remain at the top of their game. The new acquisition is one of several the company eyes in the future as part of its business growth and expansion goals.
Need for due diligence
Mr. Night regards this possible acquisition to be a tremendous step forward for the company but reminds the shareholders about due diligence as a responsibility. He says that the company is doing all within its means to speed up the process, outlining that success in this direction will enable them to set up an outstanding distribution network in the various states.
SOHM will utilize its Southern California manufacturing facility to develop its diverse products. The plan is to undertake all manufacturing activities in-house. Night believes that the company’s latest undertakings will guarantee it increased profits soon.
SOHM aspires to achieve massive business growth and stability and hopes that bringing together the two companies’ strengths will make things work out.
Mr. Night calls refers to the new deal as one of SOHM’s organic takeovers. According to the leader, they must observe due diligence, and everything must happen on a cash basis. SOHM focuses on its push for due diligence, after which it will make its definitive agreement pronouncement.
source
https://drpgazette.com/2021/04/28/sohm-inc-otcmktsshmn-set-to-acquire-a-new-pharmaceutical-company-after-signing-a-letter-of-intent/
well that is a good thing
here is what we got yesterday with out the statement of operations
https://backend.otcmarkets.com/otcapi/company/financial-report/283242/content
this the updated one you posted today
https://backend.otcmarkets.com/otcapi/company/financial-report/283247/content
again thanks for putting it up
thank you for this they had to add after becouse he is wright when i first looked at this it was not there ether they must have fixed it.
one other thing to add to the list they have a product and a market for that product
sohm there are some here who say they want prs news etc well the company is very
corresponding with share holders but they do it on twitter. twitter is a social media site and they can use it for company prs etc do to the facked they told the share holders to look there for news etc. even when you go to there site they say look at twitter as well and have there twitter page as a link.
i have been here since 0001 not sold not added its just a investment for me. not going anyplace soon going to ride this for the long haul
agreed i think we will all get a serendipity here. this is not a normal otc stock this is going to be huge. they are doing this the wright way slow and easy with no dilution or toxic notes etc. runny the company with monies form operations and growing as needed with there own cash no notes jmo
yes but if you read the whole report many of the sales are from india and other countries so when converted to u.s. dollars it dosent look like as much
you are going to have to read all the pages in full to get a full under standing of this. there is a lot of info in the report .
nice thank you
they said that the financials would be in on or before the 15th now it is up to the otc to look them over and post them that is out of the companies control
repost on some of the generic brands from sohm india
Aspa (20+500) (Sohm India) Drug Price and Information
https://www.medindia.net/drug-price/paracetamol-combination/aspa-20plus500-sohm-india.htm
Sopod (200 mg) (Cefpodoxmine Proxetil) Drug Price and Information
https://www.medindia.net/drug-price/cefpodoxmine-proxetil/sopod-200-mg.htm
Vericold (100ml) Drug Price and Information
https://www.medindia.net/drug-price/dextromethorphan-combination/vericold-100ml.htm
Rabitus D (Rabeprazole Sodium) Drug Price and Information
https://www.medindia.net/drug-price/domperidone-combination/rabitus-d.htm
Trione (1000mg) (Sterile Ceftriaxone) Drug Price and Information
https://www.medindia.net/drug-price/sterile-ceftriaxone/trione-1000mg.htm
Trione (250mg) (Sterile Ceftriaxone) Drug Price and Information
https://www.medindia.net/drug-price/sterile-ceftriaxone/trione-250mg.htm
Trione (500mg) (Sterile Ceftriaxone) Drug Price and Information
https://www.medindia.net/drug-price/sterile-ceftriaxone/trione-500mg.htm
look here
Aspa (20+500) (Sohm India) Drug Price and Information
https://www.medindia.net/drug-price/paracetamol-combination/aspa-20plus500-sohm-india.htm
Sopod (200 mg) (Cefpodoxmine Proxetil) Drug Price and Information
https://www.medindia.net/drug-price/cefpodoxmine-proxetil/sopod-200-mg.htm
Vericold (100ml) Drug Price and Information
https://www.medindia.net/drug-price/dextromethorphan-combination/vericold-100ml.htm
Rabitus D (Rabeprazole Sodium) Drug Price and Information
https://www.medindia.net/drug-price/domperidone-combination/rabitus-d.htm
Trione (1000mg) (Sterile Ceftriaxone) Drug Price and Information
https://www.medindia.net/drug-price/sterile-ceftriaxone/trione-1000mg.htm
Trione (250mg) (Sterile Ceftriaxone) Drug Price and Information
https://www.medindia.net/drug-price/sterile-ceftriaxone/trione-250mg.htm
Trione (500mg) (Sterile Ceftriaxone) Drug Price and Information
https://www.medindia.net/drug-price/sterile-ceftriaxone/trione-500mg.htm
sounds good we will have to wait and see